grant
DEVELOPMENT OF ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAS) FOR NINDS NIH BLUEPRINT NEUROTHERAPEUTICS (BPN) BIOLOGICS PROJECT
Organization BATTELLE CENTERS/PUB HLTH RES & EVALUATNLocation COLUMBUS, UNITED STATESPosted 7 Feb 2023Deadline 6 Feb 2028
NIHUS FederalResearch GrantFY2025AntibodiesAntibody TherapyBiological AgentBiological ProductsBrainBrain Nervous SystemCharacteristicsClinical TrialsCooperative AgreementsDevelopmentDucheneDuchenneDuchenne muscular dystrophyDuchenne-Griesinger syndromeELISAEllis-van Creveld (EvC) syndromeEncephalonEnzyme-Linked Immunosorbent AssayEvaluationFundingGoalsIn VitroKnowledgeLeadMissionNINDSNational Institute of Neurological Diseases and StrokeNational Institute of Neurological Disorders and StrokeNational Institutes of HealthNervous SystemNervous System DiseasesNervous System DisorderNeurologic Body SystemNeurologic DisordersNeurologic Organ SystemNeurological DisordersPb elementPersonsPseudohypertrophic Muscular DystrophyU-Series Cooperative AgreementsUnited States National Institutes of HealthX-linked dilated cardiomyopathyX-linked muscular dystrophyX-linked recessive muscular dystrophyantibody based therapiesantibody treatmentantibody-based therapeuticsantibody-based treatmentbenign X-linked recessive muscular dystrophybiologicsbiopharmaceuticalbiotherapeutic agentchildhood pseudohypertrophic muscular dystrophyclassic X-linked recessive muscular dystrophyclinical candidatedevelop therapydevelopmentalenzyme linked immunoassayheavy metal Pbheavy metal leadin vivointervention developmentlead optimizationmanufacturemild X-linked recessive muscular dystrophyneurological diseasepre-clinical studypreclinical studyprogressive muscular dystrophy of childhoodpseudohypertrophic adult muscular dystrophypseudohypertrophic muscular paralysistherapy developmenttreatment development
Description preview
The National Institute of Neurological Disorders and Stroke (NINDS), via its Blueprint (BPNBiologics)
network, is funding a cooperative agreement for the development of an antibody
for treatment of Duchenne’s muscular
dystrophy (DMD). The goals of the BPN-Biologics cooperative agreement are to optimize the
lead antibody, evaluate short-term in…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click